Nano Pharmaceuticals
Market Cap
₹95 ₹95.00 Cr.
P/E
46.41
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

  • Concord Drugs
  • Parmax Pharma
  • Mercury Laboratories

FAQs on Concord Drugs Ltd. Shareprice

Concord Drugs has given better returns compared to its competitors.
Concord Drugs has grown at ~15.46% over the last 1yrs while peers have grown at a median rate of 2.59%

Concord Drugs is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Concord Drugs is 48.63, while 3 year average PE is 59.48.
Also latest EV/EBITDA of Concord Drugs is 19.37 while 3yr average is 15.07.

Growth Table

  • Concord Drugs Ltd.
  • Parmax Pharma
  • Mercury Laboratories

Balance Sheet

  • Concord Drugs Ltd.
  • Parmax Pharma
  • Mercury Laboratories

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Concord Drugs Ltd.
  • Parmax Pharma
  • Mercury Laboratories

Cash Flow

  • Concord Drugs Ltd.
  • Parmax Pharma
  • Mercury Laboratories

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Concord Drugs Ltd.
  • Parmax Pharma
  • Mercury Laboratories

Quarterly Results

  • Concord Drugs Ltd.
  • Parmax Pharma
  • Mercury Laboratories

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Concord Drugs Ltd. Financials

Balance sheet of Concord Drugs is strong.
But short term working capital might become an issue for this company.

The net debt of Concord Drugs is decreasing.
Latest net debt of Concord Drugs is ₹12.85 Crs as of Mar-26.
This is less than Mar-25 when it was ₹18.91 Crs.

The profit is oscillating.
The profit of Concord Drugs is ₹2.05 Crs for TTM, ₹0.34 Crs for Mar 2025 and ₹0.47 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech